Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 968 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Group Regimen Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone

NCT01555164
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo to match ranolazine, Metformin, Placebo to match metformin, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
60
States / cities
Gulf Shores, Alabama • Little Rock, Alaska • Chandler, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2014 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Fasting-Mimicking Diet on Skin Health

NCT05564624
View directory record Official record
Conditions
Skin
Interventions
Fasting mimicking diet (FMD)
Other
Lead sponsor
L-Nutra Inc
Industry
Eligibility
35 Years to 60 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 21, 2026, 4:01 AM EDT
Not listed No phase listed Observational

Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis

NCT01486524
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Sirius Genomics Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

NCT02760407
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Olokizumab 64mg q4w, Olokizumab 64mg q2w, Adalimumab 40mg q2w, Placebo q2w
Drug
Lead sponsor
R-Pharm International, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
64
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 4:01 AM EDT
Recruiting Not applicable Interventional

Virtual Reality Attention Management

NCT03221244
View directory record Official record
Conditions
ADHD
Interventions
VR Treatment, VR Active Control
Device
Lead sponsor
University of California, Davis
Other
Eligibility
8 Years to 12 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 4:01 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Non-opioids for Analgesia After Adenotonsillectomy in Children

NCT03618823
View directory record Official record
Conditions
Adenotonsillectomy, Post-operative Analgesia, Opioid Use
Interventions
Oxycodone, Ibuprofen, Acetaminophen
Drug
Lead sponsor
David Chi, MD
Other
Eligibility
3 Years to 17 Years
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Not applicable Interventional Results available

At-home Auditory Training Clinical Trial

NCT01950013
View directory record Official record
Conditions
Presbycusis, Aging, Hearing Loss
Interventions
Auditory training program, Sham Comparator: Active Control
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
55 Years to 79 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

NCT03373435
View directory record Official record
Conditions
Postbariatric Hypoglycemia
Interventions
exendin 9-39, Placebo
Drug · Other
Lead sponsor
Eiger BioPharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Not applicable Interventional Results available

Northwestern University and Access Community Health Network Medication Education Study

NCT01578577
View directory record Official record
Conditions
Hypertension
Interventions
EHMI, Nurse Educator + EHMI
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 4 Interventional

Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation

NCT00087581
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Mycophenolate mofetil, Cyclosporine, Tacrolimus
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
13 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
57
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bakersfield, California + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Bacterial Decolonization to Prevent Radiation Dermatitis

NCT03883828
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
Chlorhexidine gluconate solution, Mupirocin Ointment
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 21, 2026, 4:01 AM EDT
Not listed Not applicable Interventional

Comparison of Virtual Pelvic Floor Physical Therapy With a Pelvic Floor Trainer in the Treatment of Stress Urinary Incontinence.

NCT06097234
View directory record Official record
Conditions
Stress Urinary Incontinence, Pelvic Floor Disorders
Interventions
Pelex Upp, Pelvic Floor Physical Therapy
Device · Behavioral
Lead sponsor
Pelex
Industry
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Little Neck, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 3 Interventional

Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor

NCT00006734
View directory record Official record
Conditions
Sarcoma
Interventions
filgrastim, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, adjuvant therapy, conventional surgery, neoadjuvant therapy, brachytherapy, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
0 Years to 50 Years
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2023
U.S. locations
212
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 21, 2026, 4:01 AM EDT
Recruiting Not applicable Interventional

Prehabilitation Feasibility Among Older Adults Undergoing Transplantation

NCT05642884
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Multi-modal Exercise Regimen, Dietary Guidelines
Other · Behavioral
Lead sponsor
Noha Mohamed Sharafeldin
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 21, 2026, 4:01 AM EDT
Recruiting Phase 1 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT05091424
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions
Mosunetuzumab, Tocilizumab, Venetoclax, Rituximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
5
States / cities
Rochester, Minnesota • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 4:01 AM EDT
Terminated Phase 3 Interventional Results available

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

NCT00089141
View directory record Official record
Conditions
Cancer
Interventions
mycophenolate mofetil, placebo
Drug
Lead sponsor
Martin, Paul
Other
Eligibility
4 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
15
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy

NCT02753400
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
emixustat hydrochloride, Placebo
Drug · Other
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 21, 2026, 4:01 AM EDT
Not listed Phase 4 Interventional

Phenobarbital vs Ativan for Alcohol Withdrawal in the Intensive Care Unit

NCT04156464
View directory record Official record
Conditions
Alcohol Withdrawal, Alcohol Withdrawal Delirium
Interventions
Phenobarbital, Lorazepam
Drug
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)

NCT04681729
View directory record Official record
Conditions
Cold Urticaria
Interventions
Dupilumab SAR231893, Placebo, Non sedating H1-antihistamine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years to 80 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
San Diego, California • Boise, Idaho • Owensboro, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC

NCT03077243
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Gainesville, Florida • Jacksonville, Florida • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

NCT03193190
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Nab-Paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Fluorouracil, Atezolizumab, Cobimetinib, PEGPH20, BL-8040, Selicrelumab, Bevacizumab, RO6874281, AB928, Tiragolumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Duarte, California • San Francisco, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

NCT01167868
View directory record Official record
Conditions
Healthy
Interventions
FosD, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 21, 2026, 4:01 AM EDT
Terminated Phase 2 Interventional

Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

NCT02997189
View directory record Official record
Conditions
Cisplatin Induced Hearing Loss
Interventions
OTO-104
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
6 Months to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 21, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome

NCT03721107
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Blautix, Placebo
Biological · Other
Lead sponsor
4D pharma plc
Industry
Eligibility
18 Years to 70 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Huntsville, Alabama • Phoenix, Arizona • North Hollywood, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 21, 2026, 4:01 AM EDT